1. |
Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995[see commetns]. Cancer, 1998, 83(12): 2638-2648.
|
2. |
Konstantinidis A, Stang M, Roman SA, et al. Surgical management of medullary thyroid carcinoma. Updates Surg, 2017, 69(2): 151-160.
|
3. |
Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid, 2015, 25(6): 567-610.
|
4. |
Qu N, Shi RL, Lu ZW, et al. Metastatic lymph node ratio can further stratify risk for mortality in medullary thyroid cancer patients: a population-based analysis. Oncotarget, 2016, 7(40): 65937-65945.
|
5. |
Jin LX, Moley JF. Surgery for lymph node metastases of medullary thyroid carcinoma: a review. Cancer, 2016, 122(3): 358-366.
|
6. |
Greenblatt DY, Elson D, Mack E, et al. Initial lymph node dissection increases cure rates in patients with medullary thyroid cancer. Asian J Surg, 2007, 30(2): 108-112.
|
7. |
Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf), 1998, 48(3): 265-273.
|
8. |
Kim C, Baek JH, Ha E, et al. Ultrasonography features of medullary thyroid cancer as predictors of its biological behavior. Acta Radiol, 2017, 58(4): 414-422.
|
9. |
Oh HS, Kwon H, Song E, et al. Preoperative clinical and sonographic predictors for lateral cervical lymph node metastases in sporadic medullary thyroid carcinoma. Thyroid, 2018, 28(3): 362-368.
|
10. |
Moley JF. Medullary thyroid carcinoma: management of lymph node metastases. J Natl Compr Canc Netw, 2010, 8(5): 549-556.
|
11. |
NCCN. Evidence-Based Cancer Guidelines, Oncology Drug Compendium, Oncology Continuing Medical Education. 2018-06-30. https://www.nccn.org/.
|
12. |
Brauckhoff M, Machens A, Lorenz K, et al. Surgical curability of medullary thyroid cancer in multiple endocrine neoplasia 2B: a changing perspective. Ann Surg, 2014, 259(4): 800-806.
|
13. |
Sosa JA, Tuggle CT, Wang TS, et al. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab, 2008, 93(8): 3058-3065.
|
14. |
Tuggle CT, Roman SA, Wang TS, et al. Pediatric endocrine surgery: who is operating on our children? Surgery, 2008, 144(6): 869-877.
|
15. |
Rusinek D, Chmielik E, Krajewska J, et al. Current advances in thyroid cancer management. are we ready for the epidemic rise of diagnoses? Int J Mol Sci, 2017, 18(8): E1817.
|
16. |
Shepet K, Alhefdhi A, Lai N, et al. Hereditary medullary thyroid cancer: age-appropriate thyroidectomy improves disease-free survival. Ann Surg Oncol, 2013, 20(5): 1451-1455.
|
17. |
Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab, 2010, 95(6): 2655-2663.
|
18. |
Machens A, Hauptmann S, Dralle H. Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg, 2008, 95(5): 586-591.
|
19. |
Puccini M, Manca G, Ugolini C, et al. Interest of sentinel node biopsy in apparently intrathyroidal medullary thyroid cancer: a pilot study. J Endocrinol Invest, 2014, 37(9): 829-834.
|
20. |
Jiang K, Lei J, Chen W, et al. Association of the preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios with lymph node metastasis and recurrence in patients with medullary thyroid carcinoma. Medicine (Baltimore), 2016, 95(40): e5079.
|
21. |
Jiang K, Lei J, Li C, et al. Comparison of the prognostic values of selected inflammation based scores in patients with medullary thyroid carcinoma: a pilot study. J Surg Oncol, 2017, 116(3): 281-287.
|
22. |
De Crea C, Raffaelli M, Milano V, et al. Intraoperative high-dose calcium stimulation test in patients with sporadic medullary thyroid carcinoma is highly accurate in predicting lateral neck metastases. Surgery, 2016, 159(1): 70-76.
|
23. |
Aubert S, Berdelou A, Gnemmi V, et al. Large sporadic thyroid medullary carcinomas: predictive factors for lymph node involvement. Virchows Arch, 2018, 472(3): 461-468.
|
24. |
Skinner MA, Moley JA, Dilley WG, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med, 2005, 353(11): 1105-1113.
|
25. |
Gosnell JE, Duh QY. Medullary thyroid carcinoma-we should do better. JAMA Surg, 2018, 153(1): 59.
|
26. |
Randle RW, Balentine CJ, Leverson GE, et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery, 2017, 161(1): 137-146.
|
27. |
Essig GF Jr, Porter K, Schneider D, et al. Fine needle aspiration and medullary thyroid carcinoma: the risk of inadequate preoperative evaluation and initial surgery when relying upon FNAB cytology alone. Endocr Pract, 2013, 19(6): 920-927.
|
28. |
Simões-Pereira J, Bugalho MJ, Limbert E, et al. Retrospective analysis of 140 cases of medullary thyroid carcinoma followed-up in a single institution. Oncol Lett, 2016, 11(6): 3870-3874.
|
29. |
Kuo EJ, Sho S, Li N, et al. Risk ractors associated with reoperation and disease-specific mortality in patients with medullary thyroid carcinoma. JAMA Surg, 2018, 153(1): 52-59.
|
30. |
Randle RW, Bates MF, Schneider DF, et al. Survival in patients with medullary thyroid cancer after less than the recommended initial operation. J Surg Oncol, 2018, 117(6): 1211-1216.
|
31. |
Esfandiari NH, Hughes DT, Yin H, et al. The effect of extent of surgery and number of lymph node metastases on overall survival in patients with medullary thyroid cancer. J Clin Endocrinol Metab, 2014, 99(2): 448-454.
|
32. |
Kandil E, Gilson MM, Alabbas HH, et al. Survival implications of cervical lymphadenectomy in patients with medullary thyroid cancer. Ann Surg Oncol, 2011, 18(4): 1028-1034.
|
33. |
Rendl G, Manzl M, Hitzl W, et al. Long-term prognosis of medullary thyroid carcinoma. Clin Endocrinol (Oxf), 2008, 69(3): 497-505.
|
34. |
Siironen P, Hagström J, Mäenpää HO, et al. Lymph node metastases and elevated postoperative calcitonin: predictors of poor survival in medullary thyroid carcinoma. Acta Oncol, 2016, 55(3): 357-364.
|
35. |
Geller G, Laskin J, Cheung WY, et al. A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy. Thyroid Res, 2017, 10: 6.
|
36. |
Fialkowski E, DeBenedetti M, Moley J. Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg, 2008, 32(5): 754-765.
|
37. |
Machens A, Dralle H. Benefit-risk balance of reoperation for persistent medullary thyroid cancer. Ann Surg, 2013, 257(4): 751-757.
|
38. |
Tufano RP, Bishop J, Wu G. Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: efficacy, safety, and the association of the BRAF mutation. Laryngoscope, 2012, 122(7): 1634-1640.
|
39. |
Schneider R, Randolph GW, Sekulla C, et al. Continuous intraoperative vagus nerve stimulation for identification of imminent recurrent laryngeal nerve injury. Head Neck, 2013, 35(11): 1591-1598.
|
40. |
Schmid KW. Lymph node and distant metastases of thyroid gland cancer. Metastases in the thyroid glands. Pathologe, 2015, 36 Suppl 2: 171-175.
|
41. |
Fromigué J, De Baere T, Baudin E, et al. Chemoembolization for liver metastases from medullary thyroid carcinoma. J Clin Endocrinol Metab, 2006, 91(7): 2496-2499.
|
42. |
Wertenbroek MW, Links TP, Prins TR, et al. Radiofrequency ablation of hepatic metastases from thyroid carcinoma. Thyroid, 2008, 18(10): 1105-1110.
|
43. |
French JD, Bible K, Spitzweg C, et al. Leveraging the immune system to treat advanced thyroid cancers. Lancet Diabetes Endocrinol, 2017, 5(6): 469-481.
|
44. |
Nelkin B. Recent advances in the biology and therapy of medullary thyroid carcinoma. F1000Res, 2017, 6: 2184.
|
45. |
Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase Ⅲ trial. J Clin Oncol, 2012, 30(2): 134-141.
|
46. |
Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol, 2013, 31(29): 3639-3646.
|
47. |
Pappa T, Alevizaki M. Management of hereditary medullary thyroid carcinoma. Endocrine, 2016, 53(1): 7-17.
|